000			02053 a2200553 4500
005			20250515125005.0
264		0	_c20080805
008			200808s 0 0 eng d
022			_a1538-7445
024	7		_a10.1158/0008-5472.CAN-07-6226 _2doi
040			_aNLM _beng _cNLM
100	1		_aDechant, Michael
245	0	0	_aComplement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. _h[electronic resource]
260			_bCancer research _cJul 2008
300			_a4998-5003 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAntibodies _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntibody-Dependent Cell Cytotoxicity _xphysiology
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aCaco-2 Cells
650	0	4	_aCell Death _xdrug effects
650	0	4	_aCetuximab
650	0	4	_aComplement System Proteins _xphysiology
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Evaluation, Preclinical
650	0	4	_aEpitope Mapping
650	0	4	_aErbB Receptors _ximmunology
650	0	4	_aHumans
650	0	4	_aImmunoglobulin A _xadministration & dosage
650	0	4	_aImmunoglobulin Fab Fragments _xadministration & dosage
650	0	4	_aModels, Biological
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aPanitumumab
650	0	4	_aTumor Cells, Cultured
700	1		_aWeisner, Wencke
700	1		_aBerger, Sven
700	1		_aPeipp, Matthias
700	1		_aBeyer, Thomas
700	1		_aSchneider-Merck, Tanja
700	1		_aLammerts van Bueren, Jeroen J
700	1		_aBleeker, Wim K
700	1		_aParren, Paul W H I
700	1		_avan de Winkel, Jan G J
700	1		_aValerius, Thomas
773	0		_tCancer research _gvol. 68 _gno. 13 _gp. 4998-5003
856	4	0	_uhttps://doi.org/10.1158/0008-5472.CAN-07-6226 _zAvailable from publisher's website
999			_c18076771 _d18076771